The U.S. Food and Drug Administration has elevated a nationwide recall of thyroid tablets to Class I, its most serious risk category, after tests suggested the pills contain more hormone than the label says.
The agency assigned the Class I designation on September 22, 2026.
The recall covers one lot of Vitruvias Therapeutics Thyroid Tablets, USP 30 mg (1/2 grain), lot number 504950, with National Drug Code 69680-166-00 and an expiration date of September 30, 2026.
Vitruvias shipped 3,655 units of the affected lot nationwide between January 31 and September 30, 2025, and about 1,955 of those were sold.
Also read: How daily reading may affect your brain
What a Class I recall means
Class I is the FDA's top-severity tier. The agency defines it as "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."
In plain terms, regulators believe the risk to a person taking the drug is high enough that action cannot wait.
The issue with these tablets is potency. Each pill is supposed to deliver a fixed dose of thyroid hormone.
Testing showed the recalled lot could be superpotent, meaning stronger than intended.
Also read: Nearly 6 in 10 people with high blood pressure have never been diagnosed
For a hormone the body uses to set its metabolic pace, a small extra dose swallowed every morning adds up.
Symptoms of taking too much thyroid hormone
Too much thyroid hormone pushes the body into an overactive state doctors call hyperthyroidism.
According to the FDA notice, patients taking a superpotent thyroid tablet can experience weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, or heart rhythm disturbances.
Many of these warning signs of an overactive thyroid are easy to dismiss as stress or aging in the early weeks.
Also read: Your 'healthy' food may be less nutritious than the plain version
The heart is where the greatest short-term danger sits. Excess thyroid hormone can trigger a rapid, irregular heartbeat and, in vulnerable patients, an event severe enough to be life-threatening.
Who faces the biggest risk
Not everyone taking the recalled lot faces the same risk. The FDA warns that the greatest danger is to elderly patients, pregnant women, and infants, especially when the extra dose continues over an extended period.
Older adults are more likely to have underlying heart disease that a burst of extra thyroid hormone can push into a dangerous rhythm.
In pregnancy, too much thyroid hormone has been tied to premature delivery and low birth weight. In infants, the notice flags a risk of developmental impairment.
Also read: Roller coaster closed after reports of serious brain injuries
Do not stop the pills on your own
The most important line from the FDA is one many patients get wrong.
Anyone currently taking a tablet from lot 504950 "should not discontinue use without contacting their healthcare provider for further guidance and/or a replacement prescription," the agency says. Stopping thyroid medication cold turkey can push a person back into the underactive state the drug was prescribed to fix.
Vitruvias has told the FDA it has not received any reports of adverse events tied to this lot so far.
If you take a 30 mg thyroid tablet, pull the bottle out of the medicine cabinet and look for lot number 504950 on the label before your next dose.
Also read: Having type 2 diabetes may carry a higher cancer risk
This article is made and published by Mie Hermansen, who may have used AI in the preparation.